In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...
Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...
A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products ...
“We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental ...
FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...
Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...
In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results